283 related articles for article (PubMed ID: 15019558)
1. The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release.
Aihara K; Shimada J; Miwa T; Tottori K; Burris KD; Yocca FD; Horie M; Kikuchi T
Brain Res; 2004 Apr; 1003(1-2):9-17. PubMed ID: 15019558
[TBL] [Abstract][Full Text] [Related]
2. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
Cosi C; Carilla-Durand E; Assié MB; Ormiere AM; Maraval M; Leduc N; Newman-Tancredi A
Eur J Pharmacol; 2006 Mar; 535(1-3):135-44. PubMed ID: 16554049
[TBL] [Abstract][Full Text] [Related]
3. Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors.
Tadori Y; Forbes RA; McQuade RD; Kikuchi T
Eur J Pharmacol; 2009 Apr; 607(1-3):35-40. PubMed ID: 19217900
[TBL] [Abstract][Full Text] [Related]
4. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile.
Kiss B; Horváth A; Némethy Z; Schmidt E; Laszlovszky I; Bugovics G; Fazekas K; Hornok K; Orosz S; Gyertyán I; Agai-Csongor E; Domány G; Tihanyi K; Adham N; Szombathelyi Z
J Pharmacol Exp Ther; 2010 Apr; 333(1):328-40. PubMed ID: 20093397
[TBL] [Abstract][Full Text] [Related]
5. Partial agonist actions of aripiprazole and the candidate antipsychotics S33592, bifeprunox, N-desmethylclozapine and preclamol at dopamine D(2L) receptors are modified by co-transfection of D(3) receptors: potential role of heterodimer formation.
Novi F; Millan MJ; Corsini GU; Maggio R
J Neurochem; 2007 Aug; 102(4):1410-24. PubMed ID: 17532788
[TBL] [Abstract][Full Text] [Related]
6. In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors.
Tadori Y; Forbes RA; McQuade RD; Kikuchi T
Eur J Pharmacol; 2011 Oct; 668(3):355-65. PubMed ID: 21816144
[TBL] [Abstract][Full Text] [Related]
7. Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic.
Tadori Y; Miwa T; Tottori K; Burris KD; Stark A; Mori T; Kikuchi T
Eur J Pharmacol; 2005 May; 515(1-3):10-9. PubMed ID: 15894311
[TBL] [Abstract][Full Text] [Related]
8. Functional potencies of dopamine agonists and antagonists at human dopamine D₂ and D₃ receptors.
Tadori Y; Forbes RA; McQuade RD; Kikuchi T
Eur J Pharmacol; 2011 Sep; 666(1-3):43-52. PubMed ID: 21658377
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacology of antipsychotics at human dopamine D2 and D3 receptors].
Tadori Y; Kikuchi T
Nihon Shinkei Seishin Yakurigaku Zasshi; 2012 Feb; 32(1):9-18. PubMed ID: 22568121
[TBL] [Abstract][Full Text] [Related]
10. In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling.
Jordan S; Regardie K; Johnson JL; Chen R; Kambayashi J; McQuade R; Kitagawa H; Tadori Y; Kikuchi T
J Psychopharmacol; 2007 Aug; 21(6):620-7. PubMed ID: 17092971
[TBL] [Abstract][Full Text] [Related]
11. Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912.
Tadori Y; Kitagawa H; Forbes RA; McQuade RD; Stark A; Kikuchi T
Eur J Pharmacol; 2007 Nov; 574(2-3):103-11. PubMed ID: 17692841
[TBL] [Abstract][Full Text] [Related]
12. Slow dissociation of partial agonists from the D₂ receptor is linked to reduced prolactin release.
Carboni L; Negri M; Michielin F; Bertani S; Fratte SD; Oliosi B; Cavanni P
Int J Neuropsychopharmacol; 2012 Jun; 15(5):645-56. PubMed ID: 21733233
[TBL] [Abstract][Full Text] [Related]
13. Dopamine D2 receptor partial agonists display differential or contrasting characteristics in membrane and cell-based assays of dopamine D2 receptor signaling.
Jordan S; Johnson JL; Regardie K; Chen R; Koprivica V; Tadori Y; Kambayashi J; Kitagawa H; Kikuchi T
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):348-56. PubMed ID: 17070976
[TBL] [Abstract][Full Text] [Related]
14. Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways.
Urban JD; Vargas GA; von Zastrow M; Mailman RB
Neuropsychopharmacology; 2007 Jan; 32(1):67-77. PubMed ID: 16554739
[TBL] [Abstract][Full Text] [Related]
15. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors.
Burris KD; Molski TF; Xu C; Ryan E; Tottori K; Kikuchi T; Yocca FD; Molinoff PB
J Pharmacol Exp Ther; 2002 Jul; 302(1):381-9. PubMed ID: 12065741
[TBL] [Abstract][Full Text] [Related]
16. Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors.
Tadori Y; Forbes RA; McQuade RD; Kikuchi T
Eur J Pharmacol; 2008 Nov; 597(1-3):27-33. PubMed ID: 18831971
[TBL] [Abstract][Full Text] [Related]
17. Increasing the density of the D2L receptor and manipulating the receptor environment are required to evidence the partial agonist properties of aripiprazole.
Koener B; Focant MC; Bosier B; Maloteaux JM; Hermans E
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Jan; 36(1):60-70. PubMed ID: 21871520
[TBL] [Abstract][Full Text] [Related]
18. Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties.
Wood MD; Scott C; Clarke K; Westaway J; Davies CH; Reavill C; Hill M; Rourke C; Newson M; Jones DN; Forbes IT; Gribble A
Eur J Pharmacol; 2006 Sep; 546(1-3):88-94. PubMed ID: 16925992
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effects of aripiprazole on interferon-gamma-induced microglial activation via intracellular Ca2+ regulation in vitro.
Kato T; Mizoguchi Y; Monji A; Horikawa H; Suzuki SO; Seki Y; Iwaki T; Hashioka S; Kanba S
J Neurochem; 2008 Jul; 106(2):815-25. PubMed ID: 18429930
[TBL] [Abstract][Full Text] [Related]
20. Bifeprunox and aripiprazole suppress in vivo VTA dopaminergic neuronal activity via D2 and not D3 dopamine autoreceptor activation.
Etievant A; Bétry C; Arnt J; Haddjeri N
Neurosci Lett; 2009 Aug; 460(1):82-6. PubMed ID: 19450663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
